Jump to content

Lung Cancer Canada Needs Your Help


Recommended Posts

Seeking lung cancer patients who have taken or are taking osimertinib (Tagrisso) or pembrolizumab (Keytruda).

Lung Cancer Canada, the only Canadian national organization solely focused on lung cancer, is looking for NSCLC patients and caregivers who have experience with osimertinib (Tagrisso) or pemrolizumab (Keytruda).

After a drug receives approval from Health Canada, the Pan-Canadian Oncology Drug Review (pCODR) evaluates the drug and makes a recommendation on whether the drug should be publicly funded. PCODR considers both the clinical evidence and patient/caregiver experience in their decision.

Lung Cancer Canada is coordinating a submission to pCODR representing the patient voice and as such, is currently seeking patients and their caregivers, who have been on Tagrisso or Keytruda, either presently or in the past. Patients and caregivers would be asked to participate in a brief (30-60 mins) interview via teleconference to share their experience with this drug. You don’t have to be Canadian  and all personal information, including participant's identities, would be kept strictly confidential.

If you are interested in participating, contact Daniel Gillespie at dan@lungcancercanada.ca






Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.